Profound Medical Corp. (PROF)
NASDAQ: PROFHealthcareMedical DevicesUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
PROF stock chart
Technical analysisKey statistics
All statistics- Market cap
- $207.55M
- EPS (TTM)
- -$0.93
- Dividend yield
- None
- 52-week range
- 4.80 – 8.95
- Day range
- 5.66 – 6.11
- Volume / Avg
- 324.93K / 121.06K
- Beta
- —
- Shares outstanding
- 36.54M
52-week range
PROF stock today
Profound Medical (PROF) closed at $5.68 on Oct 7, down 6.58% (-$0.40), versus the S&P 500's 0.22% decline. Volume was 2.7x the average at 324.93K shares, a sign of unusually heavy trading. Shares are 36.5% below their 52-week high of $8.95, set on Jan 13, 2026 and 18.3% above the 52-week low of $4.80, in the middle of the past year's range.
PROF is down 27.8% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has lost 12.1%. Profound Medical has posted a net loss over the last twelve months (EPS of -$0.93), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Profound Medical
Company profileProfound Medical Corp. operates as a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapeutic systems for the image guided ablation of diseased tissue. The company's lead product TULSA-PRO system combines magnetic resonance imaging (MRI), robotically driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue.
- Sector
- Healthcare
- Industry
- Medical Devices
- CEO
- Dr. Arun Swarup Menawat MBA, Ph.D.
- Headquarters
- Mississauga, ON
- Employees
- 162
- Website
- profoundmedical.com
Analyst forecast
ForecastConsensus (5 analysts)
none
Avg. price target
$11.14+96.13%
- Strong buy 0
- Buy 5
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
PROF news
All PROF newsProfound Medical peers
Healthcare sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| RXSTRxSight Inc. | 4.80 | +3.23% | $199.65M | vs PROF |
| ELMDElectromed Inc. | 28.20 | -0.25% | $233.70M | vs PROF |
| STIMNeuronetics Inc. | 2.17 | -1.81% | $165.35M | vs PROF |
| TMCITreace Medical Concepts Inc. | 3.89 | -2.75% | $252.98M | vs PROF |
| QTRXQuanterix Corporation | 3.33 | -3.34% | $157.25M | vs PROF |
| INGNInogen Inc | 5.82 | +0.87% | $154.45M | vs PROF |
| TLSITriSalus Life Sciences Inc. | 4.25 | -0.47% | $261.69M | vs PROF |
| INFUInfuSystems Holdings Inc. | 13.33 | +0.45% | $265.50M | vs PROF |
Indexes, lists and sector
Appears in lists
Profound Medical stock FAQ
What is Profound Medical's stock price today?
PROF last traded at $5.68 as of Oct 7, 4:00 PM EDT, down 6.58% on the day. Prices are delayed at least 15 minutes.
Who is Profound Medical's CEO?
Dr. Arun Swarup Menawat MBA, Ph.D. is the chief executive officer of Profound Medical Corp., which has about 162 employees.
What is the PROF 52-week high?
The 52-week high for PROF is $8.95 and the 52-week low is $4.80. The stock is currently 36.5% below its high.